Texas Oncology - Baylor - US Oncology Research
Welcome,         Profile    Billing    Logout  
 5 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Becerra, Carlos
NCT04926467: Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Not yet recruiting
2
24
US
Anakinra
Baylor Research Institute
Pancreatic Adenocarcinoma
06/25
06/26
NCT04121442: Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Completed
1/2
15
US
Isunakinra, EBI-005, PD-(L)1 Inhibitor
Buzzard Pharmaceuticals, Baylor Research Institute
Solid Tumor, Adult
12/23
07/24
NCT02744287: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Feb 2023 - Feb 2023: Early P1 data in patients with metastatic castration-resistant prostate cancer at ASCO-GU 2023
Checkmark Updated data from BP-012 trial
Oct 2020 - Oct 2020: Updated data from BP-012 trial
Checkmark From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
May 2019 - Jun 2019: From BP-012 trial in advanced solid tumors at ASCO 2019 [screenshot]
More
Suspended
1/2
151
US
BPX-601, Rimiducid, AP1903
Bellicum Pharmaceuticals
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
10/25
02/26
NCT04834778: A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

Completed
1
23
US
HC-5404-FU, HC-5404
HiberCell, Inc., Covance
Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
12/23
01/24
NCT06130722: First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Recruiting
1
18
US
FL115
Suzhou Forlong Biotechnology Co.,Ltd,
Locally Advanced/Metastatic Solid Tumors
05/25
09/25
NCT06218914: A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Recruiting
1
24
US
NT-112: Autologous, engineered T Cells targeting KRAS G12D
AstraZeneca
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
08/27
08/40
KEYNOTE-E46, NCT06125197: Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Recruiting
1
22
US
TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123), KEYTRUDA®, pembrolizumab, pembrolizumab (MK-3475)
TILT Biotherapeutics Ltd., Merck Sharp & Dohme LLC
Lung Cancer
01/26
05/26
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
132
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
INDP-D101, NCT05651022: DECOY20 Study in Patients with Advanced Solid Tumors

Recruiting
1
120
US
Decoy20
Indaptus Therapeutics, Inc, Translational Drug Development
Solid Tumor, Adult
06/27
09/27
NCT05948865: A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
102
Canada, US
CPO301, SYS6010
Conjupro Biotherapeutics, Inc.
Cancer, Cancer, Lung
06/25
12/25
Orr, Douglas W
PANOVA-3, NCT03377491: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel

Completed
3
571
Europe, Canada, US, RoW
NovoTTF-200T, TTFields, Gemcitabine, nab paclitaxel
NovoCure Ltd.
Pancreas Adenocarcinoma
10/24
10/24
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
PRO1184-001, NCT05579366: Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ )

Recruiting
1/2
404
US, RoW
Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab
Genmab
Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer
04/26
10/26
NCT04844073: A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

Recruiting
1/2
258
Europe, US, RoW
TAK-186, MVC-101
Takeda
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
09/25
11/26
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
XTX101-01, NCT04896697: Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Recruiting
1/2
136
US
vilastobart (XTX101), Atezolizumab
Xilio Development, Inc., Hoffmann-La Roche
Advanced Solid Tumor
03/26
03/26
NUV-868-01, NCT05252390: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Recruiting
1/2
657
US, RoW
NUV-868, Olaparib, Lynparza, Enzalutamide, Xtandi
Nuvation Bio Inc.
Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
06/26
11/26
KEYNOTE-F25, NCT05761223: A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849

Recruiting
1/2
151
US
Phase Ia dose-escalation part of FB849 Monotherapy, FB849, Phase Ib dose-expansion of FB849 monotherapy, Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab, KEYTRUDA®, Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer)
1ST Biotherapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor
06/26
10/26
NCT05920135: First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

Recruiting
1/2
92
US, RoW
BBT-207
Bridge Biotherapeutics, Inc.
EGFR Mutant Advanced Non-Small Cell Lung Cancer
08/26
08/28
NCT05941507: A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Recruiting
1/2
300
Canada, US
LCB84, Anti-PD-1 monoclonal antibody
LigaChem Biosciences, Inc., AntibodyChem Biosciences, Inc.
Advanced Solid Tumors
01/27
05/27
NCT04247126: A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

Completed
1
105
US
SY-5609, Fulvestrant, Gemcitabine, Nab-paclitaxel
Syros Pharmaceuticals
Advanced Solid Tumor, Breast Cancer, Small-cell Lung Cancer, Pancreatic Cancer
01/23
03/23
NCT04739293: Study of ON 123300 in Patients With Advanced Cancer

Recruiting
1
36
US
ON123300, HX 301
Onconova Therapeutics, Inc.
Solid Tumors, Adult
10/24
10/24
PEEL-224-001, NCT05329103: A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

Recruiting
1
42
US
PEEL-224
Peel Therapeutics Inc
Advanced Solid Tumor
03/25
03/26
NCT06299163: NM32-2668 in Adult Patients with Selected Advanced Solid Tumors

Recruiting
1
180
US
NM32-2668
Numab Therapeutics AG
Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer, Adenocarcinoma of Lung, Triple Negative Breast Cancer, Liposarcoma, Leiomyosarcoma, Mesothelioma, Malignant, Adenocarcinoma - Gastroesophageal Junction (GEJ), Adenocarcinoma of the Stomach, Melanoma, Malignant, Renal Cell Carcinoma
12/27
12/27
NCT05569057: A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Recruiting
1
100
US
SIM1811-03, SIM0235, TNFR2 monoclonal antibody
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
06/24
03/25
TEAD-AST-101, NCT06251310: SW-682 in Advanced Solid Tumors

Recruiting
1
186
US
SW-682, Combination Therapy
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor, Mesothelioma, Malignant
01/30
06/30
DEKA-1, NCT05704985: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Recruiting
1
60
US
DK210 (EGFR), Radiation therapy, Immune checkpoint blockers, Pembrolizumab, Nivolumab, Chemotherapy, Paclitaxel, Carboplatin, Oxaliplatin, Fluorouracil, Capecitabine
DEKA Biosciences
Cancer, Solid Tumor, Colorectal Cancer, Pancreas Cancer, Non Small Cell Lung Cancer, Head and Neck Cancer, Gynecologic Cancer, Skin Cancer, Kidney Cancer
09/24
02/25
NCT05948826: First in Human Study of TORL-3-600 in Participants With Advanced Cancer

Recruiting
1
70
Canada, US
TORL-3-600
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Colorectal Cancer
09/25
09/26

Download Options